

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
 )  
**STEWART** )  
 ) Art Unit: **1645**  
Serial No. **Not yet assigned** )  
 ) Examiner:  
Filed: **Concurrently Herewith** )  
 )  
For: **METHODS AND COMPOSITIONS** )  
**FOR THERAPEUTIC INTERVENTION** )  
**IN INFECTIOUS DISEASE** )

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of each cited item is enclosed unless stated otherwise hereinbelow.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 10/079,136 filed February 20, 2002 for an earlier filing date under 35 U.S.C. § 120, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,



Sima Singadia Kulkarni

Reg. No. 43,732

KILPATRICK STOCKTON LLP  
1100 Peachtree Street  
Suite 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 19626-0213 (45454-)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>			<b>Complete if Known</b>		
			<b>Application Number</b>		
			<b>Filing Date</b>	<b>Concurrently Herewith</b>	
			<b>First Named Inventor</b>	<b>Graham Stewart</b>	
			<b>Group Art Unit</b>	<b>1645</b>	
			<b>Examiner Name</b>		
Sheet	1	of	1	Attorney Docket Number	<b>19626-0213 (45454-)</b>

<b>OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>2</sup>
	1	ASEA, A., et al., "HSP70 Stimulates Cytokine Production Through a CD14-dependent Pathway, Demonstrating its Dual Role as a Chaperone and Cytokine", <i>Nature Medicine</i> , 2000, Vol. 6, No. 4, pp. 435-442.		
	2	BONATO, V.L.D., et al., "Identification and Characterization of Protective T Cells in hsp65 DNA-Vaccinated and <i>Mycobacterium tuberculosis</i> -Infected Mice", <i>Infection and Immunity</i> , 1988, Vol. 66, No. 1, pp. 169-175.		
	3	BUCCA, G., et al., "The HspR Regulon of Streptomyces Coelicolor: a Role for the DnaK Chaperone as a Transcriptional Co-Repressor", <i>Molecular Biology</i> , 2000, Vol. 38, No. 5, pp. 1093-1103.		
	4	CASTELLINO, F., et al., "Receptor-mediated Uptake of Antigen/Heat Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways", <i>Journal of Experimental Medicine</i> , 2000, Vol. 191, No. 11, pp. 1957-1964.		
	5	GRANDVALET, C., et al., "Disruption of hspR, the Repressor Gene of the dnaK Operon in <i>Streptomyces albus</i> G", <i>Molecular Microbiology</i> , 1997, Vol. 23, No. 1, pp. 77-84.		
	6	HAYWARD, C.M.M., et al., Construction and murine immunogenicity of recombinant bacilli calmette guerin vaccines expressing the B subunit of <i>Escherichia coli</i> heat labile enterotoxin; <i>Vaccine</i> , Vol. 17, pages 1272-1281, 1999.		
	7	MUSTAFA, A.S., et al., "Identification of Promiscuous Epitopes from the Mycobacterial 65-Kilodalton Heat Shock Protein Recognized by Human SD4 <sup>+</sup> T Cells of the <i>Mycobacterium leprae</i> Memory Repertoire", <i>Infection and Immunity</i> , 1999, Vol. 67, No. 11, pp. 5683-5689.		
	8	NARBERHAUS, F., et al., "Negative Regulation of Bacterial Heat Shock Genes", <i>Molecular Microbiology</i> , 1999, Vol. 31, No. 1, pp. 1-8.		
	9	SNEWIN, V.A. et al.; Assessment of immunity to Mycobacterial infection with luciferase reporter constructs; <i>Infection and Immunity</i> , Vol. 67, No. 9, pages 4586-4593, September 1999.		
	10	SILVA, C.L., "The Potential Use of Heat-shock Proteins to Vaccinate Against Mycobacterial Infections", <i>Microbes and Infection</i> , 1999, Vol. 1, pp. 429-435.		
	11	STEWART, G.R., et al., "Overexpression of Heat Shock Proteins Reduces Survival of <i>Mycobacterium Tuberculosis</i> in the Chronic Phase of Infection", <i>Nature Medicine</i> , 2001, Vol. 7, No. 6, pp. 732-737.		
	12	YOUNG, D. et al.; Stress proteins are immune targets in leprosy and tuberculosis; <i>Proc. Natl. Acad. Sci., USA</i> ; Vol. 85, pages 4267-4270, June 1988		
	13	ZUGEL, U., et al., "Role of Heat Shock Proteins in Protection from and Pathogenesis of Infectious Diseases", <i>Clinical Microbiology Reviews</i> , 1999, Vol. 12, No. 1, pp. 19-39.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.